en · de · es · fr · pt
semax-notes.peptides9000.com › Faq › Semax Structure And Research Background — Quick Reference

Semax Structure And Research Background — Quick Reference

By Editorial Desk · published 2026-04-23 · last reviewed 2026-06-03 · Faq

If you have been reading about heptapeptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2026-06-03. Where a claim depends on a specific study, the study is described rather than over-claimed.

Semax Structure and Research Background

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.

Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.

Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.

Semax Background and Chemistry

Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Semax at a glance

PropertyValueNotes
SequenceMet-Glu-His-Phe-Pro-Gly-ProHeptapeptide; ACTH(4-10) analog extended at C-terminus
Molecular mass~813.9 DaFree peptide, unmodified
AppearanceWhite to off-white powderTypical lyophilized solid
SolubilitySoluble in water and salineAlso soluble in common aqueous buffers
Storage (solid)-20 °C, desiccatedProtect from moisture and repeated thawing

Chemical Identity and Research Background

Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Related pages on this site

Semax Peptide Structure and Origin

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Background from the literature

Nearly all elements in the periodic table form binary bromides. The exceptions are decidedly in the minority and stem in each case from one of three causes: extreme inertness and reluctance to participate in chemical reactions (the noble gases, with the exception of xenon in the very unstable XeBr2); extreme nuclear instability hampering chemical investigation before decay and transmutation (many of the heaviest elements beyond bismuth); and having an electronegativity higher than bromine's (oxygen, nitrogen, fluorine, and chlorine), so that the resultant binary compounds are formally not bromides but rather oxides, nitrides, fluorides, or chlorides of bromine. (Nonetheless, nitrogen tribromide is named as a bromide as it is analogous to the other nitrogen trihalides.) Bromination of metals with Br2 tends to yield lower oxidation states than chlorination with Cl2 when a variety of oxidation states is available. Bromides can be made by reaction of an element or its oxide, hydroxide, or carbonate with hydrobromic acid, and then dehydrated by mildly high temperatures combined with either low pressure or anhydrous hydrogen bromide gas. These methods work best when the bromide product is stable to hydrolysis; otherwise, the possibilities include high-temperature oxidative bromination of the element with bromine or hydrogen bromide, high-temperature bromination of a metal oxide or other halide by bromine, a volatile metal bromide, carbon tetrabromide, or an organic bromide. For example, niobium(V) oxide reacts with carbon tetrabromide at 370 °C to form niobium(V) bromide.

aureus, it is suggested by many public health institutions, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), to treat first with empirical therapies for S. aureus, with an emphasis on evaluating the response to initial treatment and laboratory diagnostic techniques to isolate cases of drug resistance. Due to the possibility of potential severe or fatal consequences of resistant strains, initial treatment often includes concomitant administration of multiple antimicrobial agents that are not known to show cross-resistance, so as to reduce the possibility of a resistant strain remaining inadequately treated by a single agent during the evaluation of drug response. Once a specific resistance profile has been isolated via clinical laboratory findings, treatment is often modified as indicated. Vancomycin has long been considered a drug of last resort, due to its efficiency in treating multiple drug-resistant infectious agents and the requirement for intravenous administration. Recently, resistance to even vancomycin has been shown in some strains of S. aureus (sometimes referred to as vancomycin resistant S. aureus (VRSA) or vancomycin intermediate-resistance S. aureus (VISA)), often coinciding with methicillin/penicillin resistance, prompting the inclusion of newer antibiotics, such as linezolid, that have shown efficacy in highly drug-resistant strains. There are also strains of enterococci that have developed resistance to vancomycin, referred to as vancomycin resistant enterococcus (VRE).

== Trademark dispute and grocery brand == In 2002, Boston Pizza commenced a lawsuit against Boston Market in the Federal Court of Canada over the trademark use of the word "Boston" in Canada. In its defense, Boston Market alleged that Boston Pizza's trademarks were invalid because it described a style of pizza from a specific area. The dispute continued after Boston Market ceased operations in Canada in 2004. The parties settled the dispute in 2008 under an agreement that Boston Market would not use the words "Boston" or "Boston Market" in Canada for five years for restaurants or any food or drink products (other than pre-packaged food products, but not including pizza and lasagna). Boston Market also agreed that it would not challenge Boston Pizza's use in Canada of any trademark that uses the words "Boston" or "Boston Pizza" (with certain exceptions).

== Receptor == The endogenous receptor for Substance P is neurokinin 1 receptor (NK1-receptor, NK1R). It belongs to the tachykinin receptor sub-family of GPCRs. Other neurokinin subtypes and neurokinin receptors that interact with SP have been reported as well. Amino acid residues that are responsible for the binding of SP and its antagonists are present in the extracellular loops and transmembrane regions of NK-1. Binding of SP to NK-1R results in internalization by the clathrin-dependent mechanism to the acidified endosomes where the complex disassociates. Subsequently, SP is degraded and NK-1R is re-expressed on the cell surface. Substance P and the NK1-receptor are widely distributed in the brain and are found in brain regions that are specific to regulating emotion (hypothalamus, amygdala, and the periaqueductal gray). They are found in close association with serotonin (5-HT) and neurons containing norepinephrine that are targeted by the currently used antidepressant drugs. The SP receptor promoter contains regions that are sensitive to cAMP, AP-1, AP-4, CEBPB, and epidermal growth factor. Because these regions are related to complexed signal transduction pathways mediated by cytokines, it has been proposed that cytokines and neurotropic factors can induce NK-1. Also, SP can induce the cytokines that are capable of inducing NK-1 transcription factors.

Sources: en.wikipedia.org

Reference notes

Heroin from Afghanistan enters East Africa through the Swahili Coast, from the Indian Ocean. Many of the countries in East Africa affected by drug trafficking along the southern route have high poverty levels, poor governance and security challenges. This is exacerbated by ongoing tensions and conflicts within the region, making these states especially vulnerable to organised crime and the threat of exploitation that these criminal groups pose. Heroin seizures have indicated an increase in drug flow to the region, and further utilisation of the southern route. This has led to a growth in drug use and a rise in drug injecting in countries such as Mauritius, South Africa, Nigeria and Kenya. Opiates often reach East African on dhows, which are traditional trading ships originating in Arab and South Asian countries. Dhows used for smuggling have been caught carrying up to 1,000 kg of heroin. These East African countries do have their own consumer markets for drugs, but they are also heavily used as trans-shipment ports for routes which continue onwards e.g. to Europe.

== MD Curriculum == In August 2023, the UNC School of Medicine launched the second version of its Translational Education at Carolina (TEC) curriculum, known as TEC 2.0. The original TEC curriculum, first implemented in 2014, is designed to integrate basic science courses with longitudinal patient care, allowing students to gain clinical experience earlier than in traditional curricula. It consists of three key phases through which medical students progress.

Concerns expressed by some politicians on the subject of salvia reflect those of the media, with comparisons to LSD and particular focus on "protecting our children" being echoed; and with legislative proposals following soon after news stories breaking. Some arguments against salvia have been of a preventative nature, "We need to stop this before it gets to be a huge problem not after it gets to be a huge problem," or of an imitative nature, "The Australians have clearly found a problem with it. There's obviously a risk in people taking it." Concerns about driving while under the influence of salvia have also been expressed. Opponents of more prohibitive measures against salvia argue that such reactions are largely due to an inherent prejudice and a particular cultural bias rather than any actual balance of evidence, pointing out inconsistencies in attitudes toward other more toxic and addictive drugs such as alcohol and nicotine. While not objecting to some form of legal control, in particular with regard to the sale to minors or sale of enhanced high-strength extracts, most salvia proponents otherwise argue against stricter legislation. Those advocating consideration of Salvia divinorum's potential for beneficial use in a modern context argue that more could be learned from Mazatec culture, where salvia is not really associated with notions of drug taking at all and it is rather considered as a spiritual sacrament. In light of this it is argued that Salvia divinorum could be better understood more positively as an entheogen rather than pejoratively as a hallucinogen.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are a drug class that groups together drugs that decrease pain and lower fever, and, in higher doses, decrease inflammation. The most prominent members of this group of drugs—aspirin, ibuprofen, naproxen, and diclofenac—are all available over the counter in most countries.

known as dissociation in the context of acid–base reactions. The chemical species HA is an acid that dissociates into A−, called the conjugate base of the acid, and a hydrogen ion, H+. The system is said to be in equilibrium when the concentrations of its components do not change over time, because both forward and backward reactions are occurring at the same rate. The dissociation constant is defined by

Sources: en.wikipedia.org

Frequently asked questions

What is semax?

Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.

How is semax related to ACTH?

Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.

Is semax an approved drug?

It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.

Is semax an approved medicine?

It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.

Network